NRAS and melanoma: CUMA exhibited potent and dose-dependent growth inhibitory effects against all melanoma cell lines harboring BRAF mutation (A375, A2058, B16) or NRAS mutation (SK-MEL-2, B16F10) regardless of whether they were of human or mouse origin as evidenced by the IC50 ranging 15.1–22.9 μM and 11.8–15.5 μM at 24 and 48 h treatment, respectively; whereas, for wild-type BRAF and NRAS melanoma cell line (MeWo) IC50 of 24.2 μM was observed only after 48 h treatment (Table 1).